LYP6.DE vs. NOV.DE

Last updated Jun 13, 2026

LYP6.DE (Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc) is Europe Equities fund tracking the STOXX® Europe 600, while NOV.DE (Novo Nordisk A/S) is a stock. Over the past 10 years, LYP6.DE returned 10.02%/yr vs 17.16%/yr for NOV.DE. At a 0.32 correlation, their price movements are largely independent.

Performance

LYP6.DE vs. NOV.DE - Performance Comparison

The chart below illustrates the hypothetical performance of a €10,000 investment in Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc (LYP6.DE) and Novo Nordisk A/S (NOV.DE). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, LYP6.DE achieves a 8.98% return, which is significantly higher than NOV.DE's -10.35% return. Over the past 10 years, LYP6.DE has underperformed NOV.DE with an annualized return of 10.02%, while NOV.DE has yielded a comparatively higher 17.16% annualized return.

LYP6.DE

• 1D: 1.90%
• 1M: 4.01%
• YTD: 8.98%
• 6M: 11.60%
• 1Y: 18.44%
• 3Y*: 14.24%
• 5Y*: 9.81%
• 10Y*: 10.02%

NOV.DE

• 1D: 0.21%
• 1M: -5.31%
• YTD: -10.35%
• 6M: -8.05%
• 1Y: -43.08%
• 3Y*: 4.29%
• 5Y*: 20.26%
• 10Y*: 17.16%

*Multi-year figures are annualized to reflect compound growth (CAGR)

LYP6.DE vs. NOV.DE - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
LYP6.DE Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc	8.98%	20.82%	8.25%	15.97%	-10.40%	24.81%	-1.72%	28.59%	-11.28%	11.31%
NOV.DE Novo Nordisk A/S	-10.35%	-45.88%	-9.45%	201.62%	32.53%	76.94%	16.00%	38.98%	-7.34%	39.52%

Correlation

The correlation between LYP6.DE and NOV.DE is 0.31, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.31
Correlation (3Y) Calculated over the trailing 3-year period	0.27
Correlation (5Y) Calculated over the trailing 5-year period	0.27
Correlation (10Y) Calculated over the trailing 10-year period	0.29
Correlation (All Time) Calculated using the full available price history since Apr 3, 2013	0.32

Return for Risk

LYP6.DE vs. NOV.DE — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

LYP6.DE

LYP6.DE Risk / Return Rank: 47
LYP6.DE Sharpe Ratio Rank: 45
LYP6.DE Sortino Ratio Rank: 47
LYP6.DE Omega Ratio Rank: 47
LYP6.DE Calmar Ratio Rank: 45
LYP6.DE Martin Ratio Rank: 50

NOV.DE

NOV.DE Risk / Return Rank: 12
NOV.DE Sharpe Ratio Rank: 9
NOV.DE Sortino Ratio Rank: 11
NOV.DE Omega Ratio Rank: 10
NOV.DE Calmar Ratio Rank: 12
NOV.DE Martin Ratio Rank: 17

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

LYP6.DE vs. NOV.DE - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc (LYP6.DE) and Novo Nordisk A/S (NOV.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	LYP6.DE	NOV.DE	Difference
Sharpe ratio: Return per unit of total volatility	1.41	-0.85	+2.26
Sortino ratio: Return per unit of downside risk	2.06	-1.07	+3.13
Omega ratio: Gain probability vs. loss probability	1.26	0.85	+0.42
Calmar ratio: Return relative to maximum drawdown	1.94	-0.80	+2.74
Martin ratio: Return relative to average drawdown	7.50	-1.16	+8.65

LYP6.DE vs. NOV.DE - Sharpe Ratio Comparison

The current LYP6.DE Sharpe Ratio is 1.41, which is higher than the NOV.DE Sharpe Ratio of -0.85. The chart below compares the historical Sharpe Ratios of LYP6.DE and NOV.DE, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

LYP6.DE vs. NOV.DE - Drawdown Comparison

The maximum LYP6.DE drawdown since its inception was -35.51%, smaller than the maximum NOV.DE drawdown of -76.24%. Use the drawdown chart below to compare losses from any high point for LYP6.DE and NOV.DE.

Drawdown Indicators

	LYP6.DE	NOV.DE	Difference
Max Drawdown Largest peak-to-trough decline	-35.51%	-76.24%	+40.73%
Max Drawdown (1Y) Largest decline over 1 year	-9.45%	-53.78%	+44.33%
Max Drawdown (3Y) Largest decline over 3 years	-16.26%	-76.24%	+59.98%
Max Drawdown (5Y) Largest decline over 5 years	-20.71%	-76.24%	+55.53%
Max Drawdown (10Y) Largest decline over 10 years	-35.51%	-76.24%	+40.73%
Current Drawdown Current decline from peak	-0.24%	-70.33%	+70.09%
Average Drawdown Average peak-to-trough decline	-5.23%	-11.57%	+6.34%
Ulcer Index Depth and duration of drawdowns from previous peaks	2.45%	35.53%	-33.08%

Volatility

LYP6.DE vs. NOV.DE - Volatility Comparison

The current volatility for Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc (LYP6.DE) is 4.31%, while Novo Nordisk A/S (NOV.DE) has a volatility of 9.39%. This indicates that LYP6.DE experiences smaller price fluctuations and is considered to be less risky than NOV.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	LYP6.DE	NOV.DE	Difference
Volatility (1M) Calculated over the trailing 1-month period	4.31%	9.39%	-5.08%
Volatility (6M) Calculated over the trailing 6-month period	10.85%	37.99%	-27.14%
Volatility (1Y) Calculated over the trailing 1-year period	13.06%	50.46%	-37.40%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	14.43%	57.30%	-42.87%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	15.56%	44.50%	-28.94%

Dividends

LYP6.DE vs. NOV.DE - Dividend Comparison

LYP6.DE has not paid dividends to shareholders, while NOV.DE's dividend yield for the trailing twelve months is around 4.10%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
LYP6.DE Amundi Core STOXX Europe 600 (DR) UCITS ETF Acc	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOV.DE Novo Nordisk A/S	4.10%	3.54%	1.59%	1.02%	2.36%	2.54%	3.97%	4.18%	5.34%	4.55%	7.38%	2.50%

Frequently Asked Questions

Can I hold both LYP6.DE and NOV.DE in my portfolio?

LYP6.DE and NOV.DE have a correlation of 0.31, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.